过去未见吗导敏(molsidomine)对充血性心力衰竭长期效果的报导,本文报导双盲随机研究:Ⅰ期研究系对23名严重充血性心力衰竭患者测量口服单剂2或4毫克吗导敏后的血流动力学效应并与安慰剂比较,Ⅱ期研究系对9名32—71岁(平均47±12岁)男性口服吗导敏平均28月(7到42月),1例维持量为8毫克/日,8例至少16毫 In the past, molsidomine has been reported for the long-term effects of congestive heart failure. This article reports a double-blind, randomized study: Phase I study of 23 patients with severe congestive heart failure measured oral single dose of 2 or 4 mg? Post-hemodynamic effects were compared with placebo. The Phase II study conducted oral administration of nine men aged 32-71 years (mean, 47 ± 12 years) with an average of 28 months (range, 7 to 42 months) and one maintenance dose 8 mg / day and 8 cases at least 16 milliliters